Catalyst Wire Dossier Catalyst Wire Dossier

CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy

anti-CLL-1 CAR-T cells · Caribou Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, covering 2025-06-11 to 2025-06-11. Get the full timeline:

Most recent: Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

See pricing